Patents Assigned to FUNDACIÓ PRIVADA PARC CIENTÍFIC DE BARCELONA
-
Publication number: 20150190530Abstract: The invention relates to conjugates in which a sterol is functionalized by an ether bond with a water-soluble polymer to which a guiding ligand is bound. These conjugates improve the physico-chemical and delivery properties of their carrying vesicles, making these more stable, homogeneous and effective. A method for their preparation, a pharmaceutical composition containing said liposomes, and their therapeutic use are described as well.Type: ApplicationFiled: June 28, 2013Publication date: July 9, 2015Applicants: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), FUNDACIÓ PRIVADA PARC CIENTÍFIC DE BARCELONA, CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED EN BIONG- ENIERÍA, BIOMATERIALES Y NANOMEDICINA (CIBER-BBN), FUNDACIÓ PRIVADA INSTITUT DE RECERCA BIOMÈDICA, UNIVERSITAT DE BARCELONA, FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON- INSTITUT DE RECERCA, UNIVERSITAT AUTÒNOMA DE BARCELONAInventors: Leonor Ventosa Rull, Jaume Veciana Miró, Ingrid Cabrera Puig, Elisa Elizondo Saez De Vicuña, Marta Melgarejo Diaz, Miriam Royo Expósito, Fernando Albericio Palomera, Daniel Pulido Martinez, Santiago Sala Vergés, Jose Luis Corchero Nieto, Simón Schwartz Navarro, Ibane Abasolo Olaortua, Antonio Pedro Villaverde Corrales
-
Patent number: 8680126Abstract: Compounds of formula (I) or their pharmaceutically acceptable salts, or their stereoisomers or mixtures of stereoisomers, where: R1 is selected from the group consisting of: phenyl, and phenyl mono-, di-, or tri-substituted by a radical independently selected from the group consisting of F, Cl, Br, I, (C1-C6)-alkyl, COO—(C1-C6)-alkyl, and (C1-C6)-alkoxy; and R2 is a radical selected from the same group as R1, further including a phenyl substituted in 4-position by a radical independently selected from the group consisting of —O(CH2)CONH(CH2)3CH3 and OCH2COOC(CH3)3, a biphenyl-4-yl, thiazol-2-yl, and a thiazol-2-yl mono- or di-substituted by a radical selected from F and phenyl; inhibit cell proliferation of tumor cells independently of p53 protein and may also induce apoptosis in several tumor cells independently of p53 protein, being useful for the treatment of several types of cancer.Type: GrantFiled: August 29, 2011Date of Patent: March 25, 2014Assignees: Universitat de Barcelona, Fundacio Privada Institut d'Inbestigacio Biomedica de Bell Vitge, Fundacio Privada Institute de Recerca Biomedica de Barcelona, Fundacio Privada Parc Cientific de BarcelonaInventors: Joan Gil Santano, Rodolfo Lavilla Grifols, Fernando Albericio Palomera, Alba Pérez Perarnau, Sara Preciado Gallego, Diana Ma González Gironès, Daniel Iglesias Serret, Rosario Ramón Albalate
-
Publication number: 20130190367Abstract: Compounds of formula (I) or their pharmaceutically acceptable salts, or their stereoisomers or mixtures of stereoisomers, where: R1 is selected from the group consisting of: phenyl, and phenyl mono-, di-, or tri-substituted by a radical independently selected from the group consisting of F, Cl, Br, I, (C1-C6)-alkyl, COO-(C1-C6)-alkyl, and (C1-C6)-alkoxy; and R2 is a radical selected from the same group as R1, further including a phenyl substituted in 4-position by a radical independently selected from the group consisting of —O(CH2)CONH(CH2)3CH3 and OCH2COOC(CH3)3, a biphenyl-4-yl, thiazol-2-yl, and a thiazol-2-yl mono- or di-substituted by a radical selected from F and phenyl; inhibit cell proliferation of tumor cells independently of p53 protein and may also induce apoptosis in several tumor cells independently of p53 protein, being useful for the treatment of several types of cancer.Type: ApplicationFiled: August 29, 2011Publication date: July 25, 2013Applicants: UNIVERSITAT DE BARCELONA, FUNDACIO PRIVADA INSTITUT DE RECERCA BIOMEDICA DE BARCELONA, FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE, FUNDACIO PRIVADA PARC CIENTÍFIC DE BARCELONAInventors: Joan Gil Santano, Rodolfo Lavilla Grífols, Fernando Albericio Palomera, Alba Pérez Perarnau, Sara Preciado Gallego, Diana Mª González Gironès, Daniel Iglesias Serret, Rosario Ramón Albalate
-
Patent number: 8183006Abstract: The method comprising: a) obtaining a gene sequence codifying a naturally occurring aminoacyl-tRNA synthetase; b) engineering the gene codifying for said aminoacyl-tRNA synthetase, resulting into an aminoacyl-tRNA synthetase with a defective activity, with the proviso that the engineering does not affect the functionality of the catalytic site of the enzyme; c) cloning the gene resulting from step (b) in an expression vector; d) transforming isolated mammalian cells with the expression vector resulting from step (c); e) growing the recombinant cells resulting from step (d) in a nutrient medium under conditions which allow the expression of the engineered aminoacyl-tRNA synthetase, resulting the expression into cell death or a decrease in the rate of cell division; f) providing a substance to be tested to the medium resulting from step (e); and g) analyzing the resulting cell growth, wherein if there is an increase in cell growth, then the substance selectively inhibits the activity of the engineered aminoacylType: GrantFiled: August 30, 2007Date of Patent: May 22, 2012Assignees: Fundacio Privada Parc Cientific de Barcelona, Institucio Catalana de Recerca I Estudis AvancaInventors: Lluis Ribas De Pouplana, Teresa Bori Sanz, Manuel Castro De Moura, Renaud Geslain
-
Publication number: 20100055719Abstract: The method comprising: a) obtaining a gene sequence codifying a naturally occurring aminoacyl-tRNA synthetase; b) engineering the gene codifying for said aminoacyl-tRNA synthetase, resulting into an aminoacyl-tRNA synthetase with a defective activity, with the proviso that the engineering does not affect the functionality of the catalytic site of the enzyme; c) cloning the gene resulting from step (b) in an expression vector; d) transforming isolated mammalian cells with the expression vector resulting from step (c); e) growing the recombinant cells resulting from step (d) in a nutrient medium under conditions which allow the expression of the engineered aminoacyl-tRNA synthetase, resulting the expression into cell death or a decrease in the rate of cell division; f) providing a substance to be tested to the medium resulting from step (e); and g) analyzing the resulting cell growth, wherein if there is an increase in cell growth, then the substance selectively inhibits the activity of the engineered aminoacylType: ApplicationFiled: August 30, 2007Publication date: March 4, 2010Applicants: Fundacio Privada Parc Cientific De Barcelona, Fundacio Privada Institut De Recerca Biomedica, Institucio Catalana De Recerca I Estudis AvancatsInventors: Lluis Ribas De Pouplana, Teresa Bori Sanz, Manuel Castro De Moura, Renaud Geslain
-
Publication number: 20090291465Abstract: A screening method for identifying new drugs A screening method for identifying a candidate to drug wherein said method 5 comprises the following steps: a) obtaining an expression vector which comprises a gene sequence codifying a naturally occurring pathogenic non-discriminating tRNA synthetase; b) transforming isolated mammalian cells with the expression vector; c) growing the recombinant cells resulting from (b) in a nutrient medium under conditions which allow the expression of the 10 pathogenic tRNA synthetase, resulting the expression of the pathogenic tRNA synthetase into cell death or a decrease in the rate of cell division; d) providing a substance to be tested; and e) analyzing the resulting cell growth, wherein if there is an increase in cell growth, then the substance selectively inhibits the activity of the pathogenic tRNA synthetase and does 15 not affect to its cellular ortholog, resulting that said substance is a candidate to drug.Type: ApplicationFiled: June 28, 2007Publication date: November 26, 2009Applicants: FUNDACIÓ PRIVADA PARC CIENTÍFIC DE BARCELONA, FUNDACIÓ PRIVADA INSTITUT DE RECERCA BIOMÉDICA, INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATSInventors: Lluís Ribas De Pouplana, Teresa Bori Sanz